TY - CHAP M1 - Book, Section TI - Drug Therapy Individualization for Patients with Chronic Kidney Disease A1 - Battistella, Marisa A1 - Matzke, Gary R. A2 - DiPiro, Joseph T. A2 - Talbert, Robert L. A2 - Yee, Gary C. A2 - Matzke, Gary R. A2 - Wells, Barbara G. A2 - Posey, L. Michael Y1 - 2017 N1 - T2 - Pharmacotherapy: A Pathophysiologic Approach, 10e AB - Content UpdateAugust 1, 2018Use of Lofexidine in Opioid Withdrawal: In May 2018, the FDA approved lofexidine (Lucemyra), a central alpha-2 adrenergic agonist, for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in dependent adults. Results from two phase 3 clinical trials showed statistically significant improvement in withdrawal symptoms vs. placebo, but the improvements seen were modest and only assesed in the short-term (7 days of therapy). Use of lofexidine for opioid withdrawal symptoms in the U.S. will likely be limited to short-term, adjunctive therapy in select qualifying patients until further information becomes available. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesspharmacy.mhmedical.com/content.aspx?aid=1155626606 ER -